Last reviewed · How we verify
NCT05713981
The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression
NA trial testing Meibomian gland (MG) expression in Meibomian Gland Dysfunction in 40 participants. Completed in 8 June 2023.
8 June 2023
Quick facts
| Lead sponsor | University of the Incarnate Word |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 40 |
| Start date | 1 March 2023 |
| Primary completion | 8 June 2023 |
| Estimated completion | 8 June 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Meibomian gland (MG) expression
Conditions studied
- Meibomian Gland Dysfunction — all drugs for Meibomian Gland Dysfunction →
Sponsor
University of the Incarnate Word
Who can join
18 and older, any sex, with Meibomian Gland Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to determine the impact of Meibomian Gland Dysfunction (MGD) dry eye on low contrast black/white (luminance) and cone color sensitivity performance and improvement in these functions after in-house non-invasive Meibomian gland (MG) expression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05713981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Meibomian Gland Dysfunction
Currently open trials in the same condition.
- NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting
- NCT06371300 — Photobiomodulation With REd vs BluE Light (REBEL) · NA · recruiting
- NCT06054217 — Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex · Phase 2 · active not recruiting
- NCT03652337 — Meibomian Gland Dysfunction Management · NA · active not recruiting
Other University of the Incarnate Word trials
Trials by the same sponsor.
- NCT05482997 — Athlete Whey Protein Sensitivity: Prevalence and Performance · NA · completed
- NCT05990036 — The Outcome of Sports Vision Training on Collegiate Softball Players · NA · completed
- NCT05463016 — Impact of Color Correcting Lenses on Color Vision Deficiency · NA · completed
- NCT04808869 — Effectiveness of Blood Flow Restriction During Aerobic Cycling · NA · completed
- NCT03968731 — Meibomian Gland Dysfunction Management With ZEST Protocol · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05713981 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of the Incarnate Word
- Last refreshed: 26 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05713981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing